|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000005604 |
|
Date of registration:
|
15/05/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Evaluation of intravitreal injection of Rituximab for intraocular lymphoma
|
|
Scientific title:
|
Evaluation of intravitreal injection of Rituximab for intraocular lymphoma - Evaluation of intravitreal injection of Rituximab for intraocular lymphoma |
|
Date of first enrolment:
|
2008/06/01 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006623 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Noriyasu
Hashida |
|
Address:
|
2-2 Yamadaoka, Suita city
Japan |
|
Telephone:
|
06-6879-3456 |
|
Email:
|
nhashida@ophthal.med.osaka-u.ac.jp |
|
Affiliation:
|
Osaka University Graduate School of Medicine Department of Ophthalmology |
|
|
Name:
|
Noriyasu
Hashida |
|
Address:
|
2-2 Yamadaoka, Suita city
567-0871
Japan |
|
Telephone:
|
06-6879-3456 |
|
Email:
|
nhashida@ophthal.med.osaka-u.ac.jp |
|
Affiliation:
|
Osaka University Graduate School of Medicine Department of Ophthalmology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: The patients who has history of myocardial infarction and brain infarction.
Age minimum:
20years-old
Age maximum:
90years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
intraocular lymphoma
|
|
Intervention(s)
|
|
Intravitreal injection of Rituximab
|
|
Primary Outcome(s)
|
|
best-corrected visual acuity, intraocular pressure, indirect ophthalmoscopy, and slit-lamp examination before and after every treatment
|
|
Secondary Outcome(s)
|
|
We also evaluated whether prophylactic treatment of systemic chemotherapy such as high-dose methotrexate (HD-MTX) and intrathecal MTX (IT-MTX) or topical ocular treatments such as intravitreal injections of MTX and rituximab inhibited the onset of CNS involvement in patients with PVRL without cerebral involvement.
|
|
Source(s) of Monetary Support
|
|
Osaka University Graduate School of Medicine
|
|
Ethics review
|
Status: YES
Approval date: 31/05/2008
Contact:
nhashida@ophthal.med.osaka-u.ac.jp
Osaka University
+81668793456
nhashida@ophthal.med.osaka-u.ac.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
01/05/2013 |
|
URL:
|
|
|
|